Dopaminergic cells in the periaqueductal grey matter of MPTP-treated monkeys and mice; patterns of survival and effect of deep brain stimulation and lesion of the subthalamic nucleus

Parkinsonism and Related Disorders

Volumn 16, Issue 5, 2010, Pages 338-344

  Shaw, Victoria E ^a   Keay, Kevin A ^a   Ashkan, Keyoumars ^c   Benabid, Alim Louis ^b   Mitrofanis, John ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b CEA LETI   (France)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Brainstem; Cell death; Parkinson disease; Substantia nigra; Tyrosine hydroxylase

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; KAINIC ACID; SODIUM CHLORIDE; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN DEPTH STIMULATION; CELL COUNT; CELL FRACTIONATION; CELL SURVIVAL; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; HYPOTHALAMUS LESION; IMMUNOCYTOCHEMISTRY; MALE; MONKEY; MOUSE; NEUROPROTECTION; NONHUMAN; PERIAQUEDUCTAL GRAY MATTER; PRIORITY JOURNAL; SUBTHALAMIC NUCLEUS;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; CELL COUNT; CELL SURVIVAL; DEEP BRAIN STIMULATION; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE AGENTS; MACACA FASCICULARIS; MALE; MICE; MICE, INBRED BALB C; MPTP POISONING; NEURONS; PERIAQUEDUCTAL GRAY; SUBTHALAMIC NUCLEUS; TYROSINE 3-MONOOXYGENASE;

EID: 77952950786     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2010.02.008     Document Type: Article

References (23)

1. Larsen J., Tandberg E. Sleep disorders in patients with Parkinson's disease: epidemiology and management. CNS Drugs 2001, 15:267-275.
2. Comella C. Sleep disturbances and excessive daytime sleepiness in Parkinson disease: an overview. J Neural Transm Suppl 2006, 70:49-55.
3. Saper C., Chou T.C., Scammell T.E. The sleep switch: hypothalamic control of sleep and wakefulness. Trends Neurosci 2001, 24:726-731.
4. Lu J., Jhou T.C., Saper C.B. Identification of wake-active dopaminergic neurons in the ventral periaqueductal gray matter. J Neurosci 2006, 26:193-202.
5. Chaudhuri K.R., Schapira A.H.V. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009, 8:464-474.
6. Wallace B.A., Ashkan K., Heise C.E., Foote K.D., Torres N., Mitrofanis J., et al. Survival of midbrain dopaminergic cells after lesion or deep brain stimulation of the subthalamic nucleus in MPTP-treated monkeys. Brain 2007, 130:2129-2145.
7. Ma J., Shaw V.E., Mitrofanis J. Does melatonin help save dopaminergic cells in MPTP-treated mice?. Parkinsonism Relat Disord 2009, 15:307-314.
8. Schooner A. Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res 2004, 318:215-224.
9. Shaw V.E., Spana S., Ashkan K., Benabid A.L., Stone J., Baker G.E., et al. Neuroprotection of midbrain dopaminergic cells in MPTP-treated mice after near-infrared (NIr) light treatment. J Comp Neurol 2010, 518:25-40.
10. Paxinos G., Huang X.F., Toga A.W. The Rhesus monkey brain in stereotaxic coordinates 1998, Acad Press, USA.
11. Paxinos G., Franklin K.B.J. The mouse brain in stereotaxic coordinates 2001, Academic Press, California USA. 2nd ed.
12. Jacobowitz D.M., Palkovits M. Topographic atlas of catecholamine and acetylcholinesterase containing neurons in the rat brain. I. Forebrain (telencephalon, diencephalon). II. Hindbrain (mesencephalon, rhombencephalon). J Comp Neurol 1974, 157:13-28.
13. Hirsch E., Graybiel A.M., Agid Y.A. Melanised dopaminergic cells are differentially susceptible to degeneration in Parkinson disease. Nature 1988, 344:345-348.
14. Kastner A., Herrero M.T., Hirsch E.C., Guillen J., Luquin M.R., Javoy-Agid F., et al. Decreased tyrosine hydroxylase content in the dopaminergic neurons of MPP-intoxicated monkeys: effect of levodopa and GMl ganghoside therapy. Ann Neurol 1994, 36:206-214.
15. Flores J.A., Galan-Rodriguez B., Ramiro-Fuentes S., Fernandez-Espejo E. Role for dopamine neurons of the rostral linear nucleus and periaqueductal gray in rewarding and sensitising properties of heroin. Neuropsychopharmacology 2006, 31:1475-1488.
16. Benarroch E.E., Schmeichel A.M., Dugger B.N., Sandroni P., Parisi J.E., Low P.A. Dopamine cell loss in the periaqueductal gray in multiple system atrophy and Lewy body dementia. Neurology 2009, 73:106-112.
17. Piallat B., Benazzouz A., Benabid A.L. Subthalamic nucleus lesion in rats prevents dopaminergic nigral neuron degeneration after striatal 6-OHDA injection: behavioural and immunohistochemical studies. Eur J Neurosci 1996, 8:1408-1414.
18. Kita H., Kitai S.T. Efferent projections of the subthalamic nucleus in the rat: light and electron microscopic analysis with the PHA-L method. J Comp Neurol 1987, 260:435-452.
19. Beart P.M., Summers R.J., Stephenson J.A., Cook C.J., Christie M.J. Excitatory amino acid projections to the periaqueductal gray in the rat: a retrograde transport study utilising D[3H]aspartate and [3H]GABA. Neuroscientist 1990, 34:163-176.
20. Mitchell I.J., Clarke C.E., Boyce S., Robertson R.G., Peggs D., Sambrook M.A., et al. Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscientist 1989, 32:213-226.
21. Benabid A.L., Benazzouz A., Pollak P. Mechanisms of deep brain stimulation. Mov Disord 2002, 17(Suppl. 3):S73-S74.
22. Arnulf I., Bejjani B.P., Garma L. Improvement of sleep architecture in PD with subthalamic nucleus stimulation. Neurology 2000, 55:1732-1734.
23. Lyons K.E., Pahwa R. Effects of bilateral subthalamic nucleus stimulation on sleep, daytime sleepiness, and early morning dystonia in patients with Parkinson disease. J Neurosurg 2006, 104:502-505.